News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Advaxis, Inc. Receives Patent In Japan For ADXS-HPV For The Treatment Of Cervical Cancer


3/18/2014 9:15:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PRINCETON, N.J., March 18, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that it has been issued a significant patent from the Japan Patent Office, entitled, "Compositions and Methods for Enhancing Immunogenicity of Antigens". The claims of the patent (patent number 5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical cancer with a term that extends to 2028.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES